Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Cash from Investing Activities: 2021-2025

Historic Cash from Investing Activities for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to -$92.1 million.

  • Prime Medicine's Cash from Investing Activities fell 282.99% to -$92.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.8 million, marking a year-over-year decrease of 244.48%. This contributed to the annual value of $68.5 million for FY2024, which is 265.86% up from last year.
  • Per Prime Medicine's latest filing, its Cash from Investing Activities stood at -$92.1 million for Q3 2025, which was down 3,424.50% from $2.8 million recorded in Q2 2025.
  • Prime Medicine's 5-year Cash from Investing Activities high stood at $50.3 million for Q3 2024, and its period low was -$92.1 million during Q3 2025.
  • Moreover, its 3-year median value for Cash from Investing Activities was $2.8 million (2025), whereas its average is -$4.5 million.
  • In the last 5 years, Prime Medicine's Cash from Investing Activities skyrocketed by 401.64% in 2023 and then crashed by 282.99% in 2025.
  • Prime Medicine's Cash from Investing Activities (Quarterly) stood at $12.2 million in 2021, then crashed by 212.61% to -$13.7 million in 2022, then spiked by 401.64% to $41.3 million in 2023, then rose by 16.88% to $48.3 million in 2024, then slumped by 282.99% to -$92.1 million in 2025.
  • Its Cash from Investing Activities stands at -$92.1 million for Q3 2025, versus $2.8 million for Q2 2025 and -$47.7 million for Q1 2025.